AC Immune (ACIU) financial statements

Healthcare · Biotechnology · Market cap $253M

AC Immune reported revenue of 4M CHF in fiscal 2025, down 18.8% a year over 9 years.

Net income was -70M CHF and the operating margin -1940.1%, against -45.0% in 2016.

Free cash flow was -70M CHF.

The diluted share count rose 101% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions (CHF).

-0.1-0.100.10.10.12016201720182019202020212022202320242025RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, in CHF, from AC Immune's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Revenue23M CHF20M CHF7M CHF110M CHF15M CHF0 CHF4M CHF15M CHF27M CHF4M CHF
Research and development26M CHF33M CHF44M CHF50M CHF59M CHF62M CHF60M CHF55M CHF63M CHF56M CHF
Selling, general and admin8M CHF10M CHF12M CHF16M CHF19M CHF18M CHF16M CHF15M CHF17M CHF16M CHF
Operating income-10M CHF-23M CHF-50M CHF45M CHF-61M CHF-79M CHF-71M CHF-54M CHF-52M CHF-69M CHF
Interest expense7,000 CHF147,000 CHF298,000 CHF2M CHF184,000 CHF581,000 CHF355,000 CHF176,000 CHF133,000 CHF191,000 CHF
Pre-tax income-7M CHF-26M CHF-51M CHF45M CHF-62M CHF-73M CHF-71M CHF-54M CHF-51M CHF-70M CHF
Income tax0 CHF0 CHF0 CHF0 CHF0 CHF3,000 CHF13,000 CHF10,000 CHF3,000 CHF0 CHF
Net income-7M CHF-26M CHF-51M CHF45M CHF-62M CHF-73M CHF-71M CHF-54M CHF-51M CHF-70M CHF
EPS (diluted)-0.14 CHF-0.46 CHF-0.82 CHF0.64 CHF-0.86 CHF—————
Diluted shares50M57M62M71M72M75M84M85M100M101M
Operating margin-45.0%-111.3%-716.9%40.3%-397.0%—-1800.4%-362.3%-191.8%-1940.1%
Net margin-30.6%-130.4%-737.1%41.1%-401.3%—-1798.0%-366.4%-186.4%-1971.6%

Balance sheet

Fiscal years, in CHF, from AC Immune's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Cash and short-term investments152M CHF124M CHF156M CHF194M CHF161M CHF82M CHF32M CHF78M CHF36M CHF27M CHF
Receivables———————15M CHF0 CHF—
Total current assets155M CHF130M CHF193M CHF293M CHF232M CHF203M CHF128M CHF125M CHF172M CHF97M CHF
Property, plant and equipment1M CHF2M CHF3M CHF4M CHF4M CHF5M CHF4M CHF3M CHF3M CHF2M CHF
Total assets156M CHF132M CHF197M CHF299M CHF239M CHF261M CHF186M CHF183M CHF231M CHF154M CHF
Total current liabilities10M CHF10M CHF13M CHF18M CHF14M CHF20M CHF11M CHF14M CHF101M CHF95M CHF
Total liabilities14M CHF15M CHF19M CHF27M CHF23M CHF29M CHF17M CHF22M CHF119M CHF109M CHF
Shareholders' equity142M CHF117M CHF178M CHF272M CHF215M CHF232M CHF169M CHF161M CHF112M CHF45M CHF
Net debt-152M CHF-124M CHF-156M CHF-194M CHF-161M CHF-82M CHF-32M CHF-78M CHF-36M CHF-27M CHF

Cash flow

Fiscal years, in CHF, from AC Immune's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Operating cash flow-6M CHF-22M CHF-44M CHF55M CHF-60M CHF-66M CHF-74M CHF-60M CHF66M CHF-69M CHF
Capital spending899,000 CHF2M CHF2M CHF2M CHF2M CHF3M CHF1M CHF801,000 CHF576,000 CHF900,000 CHF
Free cash flow-7M CHF-24M CHF-46M CHF53M CHF-61M CHF-68M CHF-75M CHF-61M CHF65M CHF-70M CHF
Stock-based compensation1M CHF2M CHF3M CHF3M CHF4M CHF4M CHF3M CHF4M CHF5M CHF4M CHF
Share buybacks (net)——0 CHF0 CHF-100,000 CHF0 CHF0 CHF———
Net borrowing0 CHF200,000 CHF198,000 CHF199,000 CHF0 CHF0 CHF————
Free cash flow margin-28.2%-118.0%-664.6%48.3%-396.8%—-1901.1%-413.5%239.0%-1963.7%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ACIU.
Open ACIU in Investingly

Questions

What was AC Immune's revenue in 2025?

4M CHF in fiscal 2025, from its 10-K filing.

How much free cash flow does AC Immune generate?

-70M CHF in fiscal 2025 (operating cash flow minus capital spending).

From AC Immune's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.